Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C

Conclusions
In compensated patients with advanced fibrosis due to HCV-1, triple therapy with TVR led to satisfactory rates of safety, tolerability and on-treatment virological response with adequate managements of AEs.

Source: Gut - June 6, 2014 Category: Gastroenterology Authors: Colombo, M., Fernandez, I., Abdurakhmanov, D., Ferreira, P. A., Strasser, S. I., Urbanek, P., Moreno, C., Streinu-Cercel, A., Verheyen, A., Iraqi, W., DeMasi, R., Hill, A., Lauffer, J. M., Lonjon-Domanec, I., Wedemeyer, H. Tags: Cirrhosis, Open access Hepatology Source Type: research